Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection
Summary Low-dose human interleukin-2 (hIL-2) treatment is used clinically to treat
autoimmune disorders due to the cytokine's preferential expansion of immunosuppressive …
autoimmune disorders due to the cytokine's preferential expansion of immunosuppressive …
Engineering a single-agent cytokine/antibody fusion that selectively expands regulatory T cells for autoimmune disease therapy
IL-2 has been used to treat diseases ranging from cancer to autoimmune disorders, but its
concurrent immunostimulatory and immunosuppressive effects hinder efficacy. IL-2 …
concurrent immunostimulatory and immunosuppressive effects hinder efficacy. IL-2 …
Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species
U Karakus, D Sahin, PRE Mittl, P Mooij… - Science translational …, 2020 - science.org
Stimulation of regulatory T (Treg) cells holds great promise for the treatment of autoimmune,
chronic inflammatory, and certain metabolic diseases. Recent clinical trials with low-dose …
chronic inflammatory, and certain metabolic diseases. Recent clinical trials with low-dose …
Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology
As regulatory T cells (Tregs) play a fundamental role in immune homeostasis their adoptive
transfer emerged as a promising treatment strategy for inflammation-related diseases …
transfer emerged as a promising treatment strategy for inflammation-related diseases …
Molecular basis of selective cytokine signaling inhibition by antibodies targeting a shared receptor
Interleukin-1 (IL-1) family cytokines are potent mediators of inflammation, acting to
coordinate local and systemic immune responses to a wide range of stimuli. Aberrant …
coordinate local and systemic immune responses to a wide range of stimuli. Aberrant …
A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism
Abstract Interleukin-2 (IL-2) has been shown to suppress immune pathologies by
preferentially expanding regulatory T cells (Tregs). However, this therapy has been limited …
preferentially expanding regulatory T cells (Tregs). However, this therapy has been limited …
[HTML][HTML] Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells
CJM Bell, Y Sun, UM Nowak, J Clark, S Howlett… - Journal of …, 2015 - Elsevier
Regulatory T cells (Tregs) expressing FOXP3 are essential for the maintenance of self-
tolerance and are deficient in many common autoimmune diseases. Immune tolerance is …
tolerance and are deficient in many common autoimmune diseases. Immune tolerance is …
IL-2/CD25: a long-acting fusion protein that promotes immune tolerance by selectively targeting the IL-2 receptor on regulatory T cells
Low-dose IL-2 represents an immunotherapy to selectively expand regulatory T cells (Tregs)
to promote tolerance in patients with autoimmunity. In this article, we show that a fusion …
to promote tolerance in patients with autoimmunity. In this article, we show that a fusion …
Regulatory T cell therapy: current and future design perspectives
Regulatory T cells (Tregs) maintain immune equilibrium by suppressing immune responses
through various multistep contact dependent and independent mechanisms. Cellular …
through various multistep contact dependent and independent mechanisms. Cellular …
Engineered tolerance: tailoring development, function, and antigen-specificity of regulatory T cells
Regulatory T cells (Tregs) are potent suppressors of immune responses and are currently
being clinically tested for their potential to stop or control undesired immune responses in …
being clinically tested for their potential to stop or control undesired immune responses in …